CD Biosynsis offers high-quality Saccharomyces cerevisiae Protein Expression and Purification Services, utilizing the yeast chassis for the reliable and scalable production of complex recombinant proteins. Saccharomyces cerevisiae (baker's yeast) is a widely preferred eukaryotic host, particularly suited for expressing proteins that require post-translational modifications (PTMs), disulfide bond formation, or correct folding, which are challenging for bacterial systems like E. coli. Our comprehensive service spans from gene design (including codon optimization for yeast) and vector construction to high-cell-density fermentation and multi-step chromatography for high-purity protein isolation. We specialize in producing functional, properly folded proteins such as secreted proteins, complex therapeutic proteins, and functional enzymes, ensuring clients receive high-quality material for downstream applications in structural biology, drug screening, and diagnostics.
Get a QuoteThe key advantage of using Saccharomyces cerevisiae over prokaryotic hosts is its intrinsic eukaryotic machinery. This includes the endoplasmic reticulum (ER) and Golgi apparatus, which are essential for processing, folding, and secreting proteins that require disulfide bridges, glycosylation, or other complex PTMs for functionality. Our platform leverages optimized yeast expression vectors (both plasmid and integrated systems), tailored high-cell-density culture (HCDC) protocols, and efficient secretion systems to maximize soluble, active protein yield. This focus on eukaryotic fidelity ensures the final purified protein closely matches its native structure and function.
Codon Optimization
Rational design and optimization of the target gene sequence to match the Saccharomyces cerevisiae codon usage, enhancing translation efficiency and yield in the eukaryotic ribosomes.
Inducible Promoter Systems
Use of specialized, tightly regulated yeast promoters (e.g., GAL1, CUP1) to control protein expression, optimizing induction timing to prevent misfolding or toxicity.
Secretion Optimization
Integration of endogenous yeast signal peptides (e.g., $\alpha$-factor) to direct the protein through the ER/Golgi apparatus for extracellular secretion, simplifying downstream purification.
Affinity Chromatography (AC)
Primary capture using tags (His-tag, FLAG) or direct capture of secreted proteins from the culture supernatant, reducing initial cell lysis steps.
Protein Refolding Strategy
Custom protocols for solubilizing and correctly refolding proteins that accumulate in inclusion bodies, ensuring the final product regains its native Saccharomyces cerevisiae PTMs and structure.
Size Exclusion Chromatography (SEC)
Final polishing step used to achieve monomeric purity (>95%) and verify the protein's native oligomeric state and structural integrity.
Therapeutic/Complex Proteins
Expression of large, multi-domain proteins, cytokines, or antibody fragments (e.g., Fab) that require disulfide bond formation characteristic of the Saccharomyces cerevisiae ER.
Glycosylated Proteins
Production of proteins that require N-linked glycosylation, with options to use engineered Saccharomyces cerevisiae strains that humanize the glycan structure.
Functional Enzymes
High-yield production of complex metabolic enzymes for structural studies or industrial applications, ensuring native folding and activity.
A systematic process from gene synthesis to final quality-controlled protein.
1. Design & Vector Construction
2. High-Density Expression
3. Multi-Step Purification
4. QC & Final Delivery
Codon optimize gene for Saccharomyces cerevisiae; design purification tags and, if needed, a signal peptide for secretion.
Clone gene into optimized yeast expression vector with inducible promoter (e.g., GAL1) or integrate into the chromosome.
Transform the host strain using high-efficiency yeast transformation protocols.
Establish small-scale culture conditions to test expression, solubility, and secretion efficiency.
Scale up production using customized High-Cell-Density Culture (HCDC) media and fermentation protocols.
Induce expression at optimal cell density and harvest culture/supernatant.
Purity analysis via SDS-PAGE (>95% guaranteed) and Western Blot for identity.
Functional analysis (e.g., enzyme activity, binding kinetics) and PTM analysis upon request.
Delivery of purified protein, QC report, and documentation of expression and purification protocols.
Eukaryotic Folding & PTMs
The host provides the necessary ER/Golgi machinery to ensure correct disulfide bond formation, folding, and post-translational modifications, yielding biologically active proteins.
Secretion Capability
Utilization of native secretion pathways (e.g., $\alpha$-factor) enables protein export into the media, dramatically simplifying purification and increasing target protein purity.
Scalability & Cost-Effectiveness
Saccharomyces cerevisiae fermentation is robust, cost-effective, and easily scalable in bioreactors, making it suitable for producing large quantities of proteins at industrial standards.
Humanized Glycosylation Option
Access to specialized engineered Saccharomyces cerevisiae strains that produce human-like N-linked glycans, essential for therapeutic proteins.
1. Why is Saccharomyces cerevisiae preferred over E. coli for complex proteins?
Saccharomyces cerevisiae is a eukaryotic organism that possesses the Endoplasmic Reticulum (ER) and Golgi apparatus, which are essential for correct disulfide bond formation and PTMs, which prokaryotes like E. coli cannot perform.
2. Can the yeast system handle proteins that require disulfide bonds?
Yes. The yeast's oxidizing environment in the ER and its chaperone machinery are highly efficient at promoting the correct formation of disulfide bonds, which are critical for the activity and structure of many therapeutic proteins.
3. Do you offer "humanized" glycosylation services?
Yes. Wild-type Saccharomyces cerevisiae produces high-mannose N-glycans. We have access to engineered yeast strains that can produce more human-like N-glycans, making the system suitable for biopharmaceuticals requiring specific glycosylation profiles.
4. How is the protein purified if it is secreted?
If the protein is secreted (using a signal peptide like $\alpha$-factor), the cell biomass is removed, and the culture supernatant is subjected directly to multi-step chromatography (Affinity, IEX, SEC), greatly simplifying the purification process.
5. What quality control (QC) is performed on the final protein?
Standard QC includes SDS-PAGE for purity (>95% guaranteed), Western Blot for identity, and A280 for concentration. We also offer optional analysis for PTMs, mass spectrometry, and binding/activity assays.
6. Do you use plasmid-based or chromosomally integrated expression?
We offer both. Plasmid-based systems are rapid for small-scale production. For large-scale industrial projects, we highly recommend stable chromosomal integration using CRISPR-Cas9 to ensure consistent, reliable expression over long fermentation runs.
7. What is the role of Codon Optimization for a yeast expression project?
Codon optimization ensures that the gene sequence matches the preferred codon usage of Saccharomyces cerevisiae, minimizing translational pauses and maximizing the rate and efficiency of protein synthesis by the yeast ribosomes.
8. What is the typical turnaround time for a protein production project?
Turnaround time is competitive. While expression and fermentation take longer than in fast-growing prokaryotes, the simplified downstream purification of secreted proteins often reduces the overall time required for final delivery of high-purity material.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.